Anthera Pharmaceuticals, Inc.
ANTH
$0.00
$0.000.00%
OTC PK
| 03/31/2018 | 12/31/2017 | 09/30/2017 | 06/30/2017 | 03/31/2017 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 7.47M | 7.66M | 6.10M | 7.03M | 7.70M |
| Gross Profit | -7.47M | -7.66M | -6.10M | -7.03M | -7.70M |
| SG&A Expenses | 3.50M | 1.60M | 1.81M | 1.63M | 2.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.97M | 9.26M | 7.91M | 8.66M | 10.60M |
| Operating Income | -10.97M | -9.26M | -7.91M | -8.66M | -10.60M |
| Income Before Tax | -7.72M | -9.67M | -6.31M | 313.00K | -11.21M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.72M | -9.67M | -6.31M | 313.00K | -11.21M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.72M | -9.67M | -6.31M | 313.00K | -11.21M |
| EBIT | -10.97M | -9.26M | -7.91M | -8.66M | -10.60M |
| EBITDA | -10.81M | -9.22M | -7.87M | -8.50M | -10.56M |
| EPS Basic | -0.42 | -0.73 | -0.58 | 0.03 | -2.03 |
| Normalized Basic EPS | -0.22 | -0.46 | -0.36 | 0.02 | -0.98 |
| EPS Diluted | -0.42 | -0.73 | -0.58 | 0.03 | -2.03 |
| Normalized Diluted EPS | -0.22 | -0.46 | -0.36 | 0.02 | -0.98 |
| Average Basic Shares Outstanding | 22.17M | 13.19M | 10.95M | 10.14M | 6.76M |
| Average Diluted Shares Outstanding | 22.17M | 13.19M | 10.95M | 10.14M | 6.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |